Explore evidence

52.3 %The 3-year age-standardised net survival for cervical cancer was 52.3% in sub-Saharan Africa.

Kenyacancer du col de l'utéruspublished 2024The Lancet. Global healtheurope_pmcdocument of 12 observations

90 %From 1st July 2022 to 30th June 2023, treatment uptake for visual inspection with acetic acid (VIA) positive lesions improved from 38% pre-intervention to 90%.

Kenyacancer du col de l'utérusobserved 1st July 2022 to 30th June 2023published 2025BMC women's healthPubMeddocument of 8 observations

604,000 casesGlobally, there were about 604,000 new cervical cancer cases in 2020.

Kenyacancer du col de l'utérusobserved 2020published 2023PloS onePubMeddocument of 16 observations

52 %From 1st July 2022 to 30th June 2023, 52% of women living with HIV receiving care in 64 USAID-FYJ-supported facilities in Nairobi and Kajiado Counties received cervical cancer screening services.

Kenyacancer du col de l'utérusobserved 1st July 2022 to 30th June 2023published 2025BMC women's healthPubMeddocument of 8 observations

225 samplesCervical cancer biopsy samples processed by the histopathology lab at Moi Teaching and Referral Hospital increased from 225 in 2018 to 674 in 2022.

Kenyacancer du col de l'utérusobserved 2018published 2025BMC cancerPubMeddocument of 4 observations

212,000 DALYsAnnual vaccine supply disruptions would avert 212,000 disability-adjusted life-years (DALYs) compared with a 1-dose strategy.

Kenyacancer du col de l'utérusPubMeddocument of 6 observations

1.97 hazard_rate_ratioIn patients with FIGO stage I-III cervical cancer (n = 190), major guideline deviations were associated with impaired overall survival (hazard rate ratio, 1.97; 95% confidence interval, 0.59–6.56).

Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718

18 %18% of women with an abnormal cervical cancer screening result received treatment.

Kenyacancer du col de l'utéruspublished 2025BMC women's healthPubMeddocument of 8 observations

8.2 %Of 632 patients, 8.2% received cancer-directed therapy with major deviations from guidelines.

Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718

84 %Cervical cancer is the second most common female reproductive cancer after breast cancer, with 84% of cases occurring in developing countries.

Kenyacancer du col de l'utéruspublished 2020PloS onePubMeddocument of 5 observations

2.4 %Of 632 patients, 2.4% received cancer-directed therapy with minor deviations from guidelines.

Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718

2.5 %In the last quarter of the trial, 2.5% (37/1507) of visits with eligible family planning clients at intervention facilities included cervical cancer screening.

Kenyacancer du col de l'utéruspublished 2023Implementation science : ISeurope_pmcdocument of 5 observationsDOI 10.1186/s13012-023-01322-y

25.6 %Twenty-five point six percent (54/211) of those aware of cervical cancer reported it to be caused by Human Papilloma Virus (HPV).

Kenyacancer du col de l'utérus · Human Papilloma Virus (HPV)published 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument of 18 observations

3.7 %In the last quarter of the trial, 3.7% (66/1793) of visits with eligible family planning clients in control clinics included cervical cancer screening.

Kenyacancer du col de l'utéruspublished 2023Implementation science : ISeurope_pmcdocument of 5 observationsDOI 10.1186/s13012-023-01322-y

9 deaths per dayNine women in their twenties die from cervical cancer in Kenya every day.

Kenyacancer du col de l'utéruspublished 2020PloS onePubMeddocument of 5 observations

22 %Of 632 patients, 22% had cancer-directed therapy not documented or without curative potential.

Kenyacancer du col de l'utéruspublished 2021The oncologisteurope_pmcdocument of 14 observationsDOI 10.1002/onco.13718

Cervical cancer is a leading cause of cancer death among women of reproductive age.

Kenyacancer du col de l'utéruspublished 2024BMC women's healthPubMeddocument of 3 observations

1.34 risk_ratioKnowing someone who had cervical cancer was associated with an adjusted risk ratio of 1.34 for screening in Kenya.

Kenyacancer du col de l'utérusobserved 2022-2023published 2025BMC public healthPubMeddocument of 8 observations

45 %The prevalence rate of cisplatin-induced nephrotoxicity in cervical cancer patients was 45%.

Kenyacancer du col de l'utéruspublished 2022Journal of oncology pharmacy practice : official publication of the International Society PubMeddocument of 4 observations

24.4 %Of the surveyed facilities in Kenya, 24.4% offered cervical cancer screening services.

Kenyacancer du col de l'utérusobserved 2019–2020published 2022BMC health services researchPubMeddocument of 8 observations

67.5 %The 5-year relative survival for Stage I-II cervical cancer in high HDI registry areas was 67.5%.

Kenyacancer du col de l'utérusobserved 2005 to 2015published 2020International journal of cancereurope_pmcdocument of 6 observations

37 %Being a public FP clinic was associated with higher prevalence of reported screening (14/38 [37%] vs 6/32 [16%]; prevalence rate ratio [PR] 1.57, 95%CI 1.05-2.33).

Kenyacancer du col de l'utérusobserved 2017-2018published 2022BMC health services researcheurope_pmcdocument of 10 observationsDOI 10.1186/s12913-022-08984-2

23 %As of October 2021, 23% of Fahari ya Jamii project-supported HIV clinics in Nairobi and Kajiado Counties were offering cervical cancer screening for women living with HIV.

Kenyacancer du col de l'utérusobserved October 2021published 2025BMC women's healthPubMeddocument of 8 observations

35.6 %Cervical cancer screening uptake among women living with HIV was 35.6% in the FACES program during the study period from October 2007 to February 2019.

Kenyacancer du col de l'utérusobserved October 2007 to February 2019published 2024JCO global oncologyPubMeddocument of 6 observations

Sub-Saharan Africa has the highest rate of cervical cancer cases and deaths worldwide.

Kenyacancer du col de l'utéruspublished 2023VaccinePubMeddocument of 6 observations